Latest Litigation Risk News

The National Court of Papua New Guinea has dismissed litigation brought by offshore-funded landowners against Bougainville Copper Limited, ordering indemnity costs in the company’s favor.

Mayne Pharma reported a 5% revenue increase to $408.1 million for FY25 but posted a net loss of $93.8 million, narrowing from the prior year. The company’s planned acquisition by Cosette Pharmaceuticals faces legal hurdles, delaying completion.

Acusensus Limited reported a 20% increase in revenue to $59.35 million for FY25, driven by new and expanded contracts across Australia, New Zealand, the US, and the UK. However, net losses widened by 72.3%, reflecting higher operating expenses and ongoing litigation costs.

Transurban reports solid FY25 financial results with strong EBITDA and free cash flow growth, steady operating costs, and promising progress on NSW Toll Reform and major infrastructure projects.

ResMed Inc. reported a robust 10% increase in revenue to $5.15 billion for fiscal 2025, driven by strong demand in sleep and breathing health devices and residential care software. The company also expanded its diagnostic capabilities with the acquisition of VirtuOx, positioning itself for further growth in home-based health solutions.

Power Minerals Limited has launched a new options offer linked to a recent $1.3 million placement, alongside updates on key project acquisitions and divestments. The prospectus outlines significant risks and strategic directions as the company navigates growth and financial challenges.

Treasury Wine Estates has secured Supreme Court approval for a $65 million settlement of a consolidated shareholder class action, allowing the company to focus on its strategic goals without admitting liability.

Macarthur Minerals Limited has issued a replacement prospectus for a renounceable entitlement offer aiming to raise approximately AUD 2 million, fully underwritten by Gold Valley Yilgarn Pty Ltd. The offer includes free attaching options and supports the company’s exploration and operational funding needs.

Mayne Pharma rebuffs Cosette's claim of a material adverse change in their merger scheme and secures FDA clearance on regulatory concerns, maintaining its commitment to the deal's completion.

ALS Limited has announced a fully underwritten A$350 million equity placement to fund major upgrades to its global laboratory network and support future growth initiatives, aiming for mid single-digit EPS accretion by FY25 pro forma.

Mayne Pharma Group has proposed a $7.40 per share acquisition by Cosette Pharmaceuticals, with unanimous board support and a fair and reasonable opinion from an independent expert. Shareholders will vote on the scheme on June 18, 2025.

Fletcher Building reported a challenging HY25 with a 7% revenue decline and a net loss of NZ$134 million, while executing a $700 million equity raise to strengthen its balance sheet and advancing significant cost reduction initiatives.